Silvio E. Inzucchi, M.D. Professor of Medicine Section of Endocrinology Department of Internal Medicine 333 Cedar Street P.O. Box 208020 New Haven, CT 06520-8020 USA Email: silvio.inzucchi@yale.edu Telephone: (203) 737-1932 Fax:(203) 737-2812

• M.D., Harvard Medical School, 1985
• Internship and Residency: Yale-New Haven Hospital, 1985-88
• Endocrinology Fellowship: Yale School of Medicine, 1992-94

Dr. Inzucchi is Professor of Medicine at Yale University and attending physician at Yale-New Haven Hospital. He serves as the Clinical Director of the Section of Endocrinology, the Director of the Yale Diabetes Center, and Medical Director of the Department of Medicine's faculty practice on Dana 3. He is also consultant in endocrinology to the West Haven Veterans' Administration Medical Center and the Yale Health Plan. Dr. Inzucchi, is board-certified in Internal Medicine and Endocrinology/Metabolism, and is an active member of the Endocrine Society and the American Diabetes Association.

Dr. Inzucchi has an active clinical practice. He has published and lectured extensively on many topics in endocrinology. Dr. Inzucchi's areas of expertise include the broad range of endocrine conditions: diabetes; lipid disorders; and thyroid, pituitary and adrenal diseases. His special interests are difficult-to-manage diabetes, insulin resistance, insulin pump therapy, pituitary tumors, acromegaly, Cushing's syndrome, growth hormone replacement therapy in adults, and endocrine disorders during pregnancy.

Office hours are held every Tuesday, Wednesday and Thursday on Dana 3 (789 Howard Avenue). Dr. Inzucchi works in conjunction with Geri Spollett MSN, an adult nurse practitioner and certified diabetes educator, and Gael Ulisse APRN and Helen Psarakis APRN of Yale-New Haven Hospital's Inpatient Diabetes Management Team.

Office Address:

333 Cedar Street; LCI 101
Box 208020
New Haven, CT 06520-8020

Telephone for Appointments:

(203) 737-1932

Research

Dr. Inzucchi's research primarily involves collaborative clinical investigations into (1) the efficacy and mechanism of action of new therapeutic agents for type 2 diabetes and (2) the impact of diabetes and insulin resistance on cardiovascular disease. Other research interests include the development of guidelines for the management of diabetes in both the inpatient and outpatient settings, and in the management of the adult growth hormone deficiency syndrome.